〔Abstract〕 Objective To explore the value of integrated management intervention combined with sacubitril valsartan in the clinical treatment of patients with heart failure and renal insufficiency. Methods 100 patients with heart failure and renal insufficiency admitted to People's Hospital of Ruijin City from January 2021 to December 2021 were randomly divided into a control group and an observation group, with 50 patients in each group. The control group patients were treated with sacubitril valsartan on the basis of routine management, while the observation group patients were treated with integrated management on the basis of the control group. The cardiac function, clinical symptom improvement, quality of life, and clinical indicators between the two groups of patients were compared. Results After treatment, the levels of cardiac function testing improved in both groups of patients. The heart rate and left ventricular end systolic diameter of the observation group were lower than those of the control group, and the left ventricular ejection fraction of the observation group was higher than that of the control group, the differences were statistically significant (P < 0.05). The proportion of patients with improved clinical symptoms in the observation group was higher than that in the control group, and the difference was statistically significant (P < 0.05). After treatment, the Minnesota living with heart failure questionnaire (MLHFQ) scores of both groups of patients decreased, and the score of the observation group was lower than that in the control group, with statistical significance (P < 0.05). After treatment, the blood creatinine clearance rate and glomerular filtration rate in the observation group were higher than those in the control group, and the level of N-terminal pro-brain natriuretic peptide in the observation group was lower than that in the control group, the differences were statistically significant (P < 0.05). Conclusion The combination of sacubitril valsartan and integrated management intervention can improve the patient's treatment compatibility, while further improving the patient's prognosis and quality of life.